Please watch this info session video to learn about the benefits of applying to our exciting new BioTools Innovator Accelerator program and tips on applying. Final deadline is May 15!

Click here to learn more and apply

This recap video features comments from some of our startups and corporate partners about their experiences in the MedTech Innovator program.


Read All News →

News About Our Companies

Read All News →

Sentien Biotechnologies Completes Enrollment of First Cohort in Phase 1/2 Trial of Ex Vivo MSC Therapy for the Treatment of Severe COVID-19

Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, today announced it has completed enrollment of the first cohort in its Phase 1/2 study of SBI-101 for the treatment of severe COVID-19. SBI-101, Sentien’s innovative cell-based therapy, is being evaluated in COVID-19 patients suffering from both acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI) requiring renal replacement therapy (RRT).
Read More →

Innovator Network Partners

Helping accelerate innovation for U.S. health security

Along with several other accelerators located across the nation, MedTech Innovator is a proud member of the Division of Research, Innovation, and Ventures (DRIVe) Accelerator Network. DRIVe, a part of the Biomedical Advanced Research and Development Authority (BARDA), is a transformative public-private program designed to accelerate innovation and solve the nation’s most challenging, and cross-cutting health security threats.

This partnership aims to increase the pipeline of promising startups working on solutions that support health security preparedness. Additionally, MedTech Innovator will support selected companies with their commercialization strategies through our award-winning accelerator program. To learn more about the DRIVE initiative and to apply, visit